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Objectives This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A2 (Lp-PLA2)
inhibitor, on biomarkers of cardiovascular (CV) risk.
Background Elevated Lp-PLA2 levels are associated with an increased risk of CV events.
Methods Coronary heart disease (CHD) and CHD-risk equivalent patients (n  959) receiving atorvastatin (20 or 80 mg)
were randomized to oral darapladib 40 mg, 80 mg, 160 mg, or placebo once daily for 12 weeks. Blood samples
were analyzed for Lp-PLA2 activity and other biomarkers.
Results Baseline low-density lipoprotein cholesterol (LDL-C) was 67  22 mg/dl. Plasma Lp-PLA2 was higher in older
patients (75 years), in men, in those taking atorvastatin 20 mg, at LDL-C 70 mg/dl or high-density lipo-
protein cholesterol (HDL-C) 40 mg/dl, or in those with documented vascular disease (multivariate regression;
p  0.01). Darapladib 40, 80, and 160 mg inhibited Lp-PLA2 activity by approximately 43%, 55%, and 66%
compared with placebo (p  0.001 weeks 4 and 12). Sustained dose-dependent inhibition was noted overall in
both atorvastatin groups and at different baseline LDL-C (70 vs. 70 mg/dl) and HDL-C (40 vs. 40 mg/dl).
At 12 weeks, darapladib 160 mg decreased interleukin (IL)-6 by 12.3% (95% confidence interval [CI] 22% to
1%; p  0.028) and high-sensitivity C-reactive protein (hs-CRP) by 13.0% (95% CI 28% to 5%; p  0.15)
compared with placebo. The Lp-PLA2 inhibition produced no detrimental effects on platelet biomarkers
(P-selectin, CD40 ligand, urinary 11-dehydrothromboxane B2). No major safety concerns were noted.
Conclusions Darapladib produced sustained inhibition of plasma Lp-PLA2 activity in patients receiving intensive atorvastatin
therapy. Changes in IL-6 and hs-CRP after 12 weeks of darapladib 160 mg suggest a possible reduction in
inflammatory burden. Further studies will determine whether Lp-PLA2 inhibition is associated with favorable
effects on CV events. (SB-480848 in Subjects With Coronary Heart Disease; NCT00269048) (J Am Coll Cardiol
2008;51:1632–41) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.079R
p
fi
m
trom the *University of Pennsylvania School of Medicine, Philadelphia, Pennsylva-
ia; †Baylor College of Medicine and Methodist DeBakey Heart Center, Houston,
exas; ‡Radiant Research, Rush University Medical Center, Chicago, Illinois;
Center for Clinical Studies, Dresden, Germany; Hospital 12 de Octubre, Madrid,
pain; ¶GlaxoSmithKline, Philadelphia, Pennsylvania, and Research Triangle Park,
orth Carolina; and #Thomas Jefferson University, Philadelphia, Pennsylvania.t
Manuscript received September 26, 2007; revised manuscript received November 7,
007, accepted November 21, 2007.esidual risk of cardiovascular (CV) events persists even in
atients with aggressively controlled risk factors (1). These
ndings suggest the presence of additional modifiable
See page 1642
echanisms of the underlying atherosclerotic process. To
his end, atherosclerosis initiation, its progression, and the
ransition to acute coronary syndromes (e.g., due to plaque
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April 29, 2008:1632–41 Lp-PLA2 and Cardiovascular Biomarkersupture) are accompanied by focal inflammation in lesion-
rone areas (2). In addition, elevated levels of circulating
nflammatory biomarkers have been reported in several
opulations at risk (3,4). Recent clinical trials further
mplied that achieving lower levels of high-sensitivity
-reactive protein (hs-CRP) in conjunction with aggressive
ow-density lipoprotein cholesterol (LDL-C)–lowering
70 mg/dl) are associated with reduced progression of
oronary atheroma and fewer CV events (5,6). Nevertheless,
tatin trials offer only indirect evidence of the link between
nflammation and clinical events because of the primary
enefit of concomitant lipid-lowering (7). Other treatments
hat are proven to reduce CV events lack consistent anti-
nflammatory effects in the clinical setting (e.g., aspirin or
ngiotensin-converting enzyme inhibitors) (8). Thus, the
ausal role of inflammation in the progression of atheroscle-
otic vascular disease and CV events remains to be proven by
harmacologic interventions that specifically target the in-
ammatory cascade.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is
n emerging biomarker of CV risk that is pharmacologically
odifiable and therefore well positioned to address novel
echanisms of atherosclerotic vascular disease. Lipoprotein-
ssociated phospholipase A2 is produced by inflammatory
ells involved in atherogenesis (macrophages, T cells, mast
ells), is predominantly bound to atherogenic lipoproteins,
nd accumulates in human atherosclerotic lesions (9). Al-
hough this enzyme has been referred to as platelet-
ctivating factor-acetylhydrolase (PAF-AH), Lp-PLA2 ex-
ibits much broader substrate specificity (10,11). In
articular, Lp-PLA2 rapidly degrades polar phospholipids
resent in oxidized LDL-C, releasing downstream products
uch as lysophosphatidylcholine species and oxidized non-
sterified fatty acids (12). These products of the Lp-PLA2
eaction exhibit a wide range of pro-inflammatory and
ro-apoptotic effects in experimental settings (9). In this
ontext, Lp-PLA2 could be proposed as the enzyme that
inks oxidized LDL-C with atherosclerosis progression and
laque vulnerability. This hypothesis is supported by studies
hat suggest increased risk of CV events with elevated levels
f circulating Lp-PLA2, the presence of high expression of
p-PLA2 in apoptotic macrophages in high-risk human
oronary lesions, and the ability to alter the phenotype of
nflammatory cells with Lp-PLA2 inhibition in vitro (13–
8). The view of Lp-PLA2 as a pro-atherogenic enzyme,
owever, has not been uniformly accepted, because of
ontradictory results of Lp-PLA2 overexpression in preclin-
cal models of atherosclerosis, a theoretical concern that
nhibition of Lp-PLA2 might lead to increase in platelet
ctivation, and conflicting data with a genetic variant of
p-PLA2 in Japanese subjects (9,19).
In this study, we sought to investigate whether darapladib
SB-480848), a selective Lp-PLA2 inhibitor, produces sus-
ained inhibition of plasma Lp-PLA2 activity in CV pa-
ients treated aggressively with atorvastatin. In addition, the lffects of darapladib on several
V biomarkers of risk and safety
ere examined.
ethods
tudy design. The multicen-
er, randomized, double-blind,
lacebo-controlled, parallel-group
tudy that was conducted in 110
ites in 15 countries from Novem-
er 2005 to June 2006 (a list of
nvestigators is provided in the
nline Appendix). This dose-
anging study evaluated the ability
f darapladib to produce sustained
nhibition of plasma Lp-PLA2 ac-
ivity in subjects with stable coro-
ary heart disease (CHD) or
HD-risk equivalent receiving
oncomitant atorvastatin therapy. Those subjects not currently
eceiving statin therapy first received open-label atorvastatin 20
g for 2 weeks. All eligible subjects were initially randomized
o double-blind atorvastatin 20 or 80 mg once daily (Fig. 1).
fter 4 weeks, subjects who tolerated atorvastatin therapy and
chieved LDL-C levels of115 mg/dl were then randomized
o concomitant administration of darapladib 40 mg, 80 mg,
60 mg, or placebo once daily for 12 weeks. After discon-
inuing darapladib or placebo, subjects continued on
ouble-blind atorvastatin for an additional 2 weeks. Ethics
ommittees approved the protocol, and all subjects provided
ritten informed consent before enrollment in the study.
tudy subjects. Subjects ages 18 to 80 years with stable
HD or CHD-risk equivalent (defined as diabetes mellitus
equiring hypoglycemic medication; carotid stenosis 50%;
rior carotid surgery or stenting; peripheral arterial disease;
r a cluster of risk factors resulting in 10-year risk for
oronary events 20% according to Framingham Risk
core) were eligible for screening. Main exclusion criteria
ere CV event or vascular procedure within the preceding 6
onths, contraindications to double-blind atorvastatin
herapy, serum triglycerides 400 mg/dl, elevated liver
unction tests (alanine transaminase, aspartate transaminase,
lkaline phosphatase, or total bilirubin 1.5  ULN),
emoglobin subtype A1c 10%, chronic inflammatory
iseases, inadequately controlled hypertension (160 mm
g systolic or 100 mm Hg diastolic), renal disorder
serum creatinine 2.5 mg/dl), severe congestive heart
ailure (New York Heart Association functional class III or
V), and prolonged QTc interval (440 ms for men or
450 ms for women).
ssessments. Blood assessments were carried out in the
asting state at baseline (before randomization to darapladib
r placebo) and at 4 and 12 weeks of dosing with darapladib
r placebo. These included total cholesterol, high-density
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CV  cardiovascular
HDL-C  high-density
lipoprotein cholesterol
hs-CRP  high-sensitivity
C-reactive protein
IL  interleukin
LDL-C  low-density
lipoprotein cholesterol
Lp-PLA2  lipoprotein-
associated phospholipase A2
PAF-AH  platelet-
activating factor-
acetylhydrolaseipoprotein-cholesterol (HDL-C), calculated LDL-C, tri-
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Lp-PLA2 and Cardiovascular Biomarkers April 29, 2008:1632–41lycerides, and routine safety labs. In addition, plasma
p-PLA2 activity, inflammatory biomarkers, and platelet-
elated biomarkers were measured at baseline and at 4 and
2 weeks approximately 24 h after dosing with darapladib
r placebo. Plasma Lp-PLA2 activity and platelet-related
iomarkers were also measured 2 weeks after discontinuing
arapladib or placebo. Supine vital signs were collected at
aseline, 4, 8, and 12 weeks, and 2 weeks after discontinuing
arapladib or placebo; a physical examination and electro-
ardiogram were also performed at baseline and at 4 and
2 weeks.
iochemical parameters. The Lp-PLA2 activity was mea-
ured in plasma by a colorimetric assay as previously
escribed (20). The assay characteristics included intra-assay
recision of 1.7% and inter-assay precision of 4.8%. In a subset
f subjects, Lp-PLA2 activity also was measured by a
adiometric assay with [3H]-platelet-activating factor as a
ubstrate (21). The assay (Quest Diagnostics, Lyndhurst,
ew Jersey) included intra-assay precision: low 3.0%, mid
.5%, high 2.2% and interassay precision: low 6.5%, mid
.4%, high 8.8%. Details regarding the analysis of the
emaining biomarkers are provided online.
tatistical analyses. The primary efficacy end point was
ustained inhibition of plasma Lp-PLA2 activity measured
s the change from 4 to 12 weeks at trough levels of
arapladib. The primary comparison was based on 2-sided
5% confidence intervals (CIs) for the change in log-
ransformed Lp-PLA2 activity from week 4 to week 12 for
ach darapladib group. Sample size was calculated with an
D for change in log-transformed Lp-PLA2 activity values
Figure 1 Subject Disposition
All eligible subjects were initially randomized to double-blind atorvastatin 20 or 80
achieved low-density lipoprotein cholesterol levels of 115 mg/dl were then rando
once daily for 12 weeks. The number of subjects and reason for discontinuation af 0.34 from a previous study, an equivalence limit of 0.883 po 1.132 (equivalent to  0.124 on the log scale), and 90%
ower. With these assumptions, 196 subjects/group were
equired, without adjustment for multiplicity or atorvastatin
reatment group. Thus, assuming a 15% dropout rate, a
inimum of 920 subjects (or 230/treatment group) were
lanned to be randomized.
Secondary end points included dose-response of darapladib
ver log-transformed Lp–PLA2 activity and changes in
nflammatory biomarkers and platelet-related biomarkers. Pri-
ary and secondary end points of changes in Lp-PLA2 activity
nd inflammatory and platelet-related biomarkers were all
ssessed with analysis of covariance. Treatment group and
torvastatin doses (20 and 80 mg) were included in all
tatistical models, with baseline values also included for
nflammatory and platelet-related biomarkers. Interactions
or atorvastatin level by treatment group were tested at the
0% significance level. Correlations were assessed with
earson product moment correlation coefficients.
esults
tudy population and baseline characteristics. Figure 1
epicts subject flow through the study. A total of 1,410
ubjects were screened for eligibility, 1,082 were assigned to
ouble-blind atorvastatin, and 964 subjects were subsequently
andomized to darapladib or placebo. Five of these subjects did
ot receive any dose of darapladib or placebo; therefore 959
ubjects were included in the analyses. The exposure to
arapladib or placebo was 81  13 days (mean  SD).
Baseline characteristics of the subject population are
ce daily. After 4 weeks, subjects who tolerated atorvastatin therapy and
to concomitant administration of darapladib 40 mg, 80 mg, 160 mg, or placebo
icted in this figure.mg on
mized
re depresented in Table 1. At study entry, 75% of subjects were
r
s
o
m
a
3
B
l
s
L
r
d
v
o
n
r
c
b
v
l
L
w
L
w
E
b
r
4
a
c
L
m
a
p
s
l
c
m
t
8
(
4
a
3
a
r
c
w
1
L
L
m
r
(
1
m
L
m
L
s
H
s
l
e
1
e
e
w
v
t
l
t
B
*
p
2
b
p
a
1635JACC Vol. 51, No. 17, 2008 Mohler III et al.
April 29, 2008:1632–41 Lp-PLA2 and Cardiovascular Biomarkerseceiving statin therapy. As required by the protocol, all
ubjects were assigned atorvastatin and received a high level
f contemporary medical care. Demographic data, past
edical history, and concomitant treatments were balanced
mong subgroups of subjects randomized to placebo or the
dosing regimens of darapladib.
aseline Lp-PLA2 activity. As shown in Table 2, baseline
evels of Lp-PLA2 activity were significantly higher in older
ubjects, in men, in nondiabetic patients, in those with
DL-C 70 mg/dl or HDL-C 40 mg/dl, in those
eceiving the lower dose of atorvastatin, and in those with
ocumented vascular disease. Diabetic subjects had lower
alues of Lp-PLA2 activity than nondiabetic subjects, likely
wing to lower LDL-C levels (diabetic: 64  1 mg/dl vs.
ondiabetic: 71  1 mg/dl, p  0.001). In the multivariate
egression analysis, all of these variables remained statisti-
ally significant (p  0.01) except for diabetic status. When
aseline Characteristics of Study Population
Table 1 Baseline Characteristics of Study Population
Demographic data
Age, yrs (mean)* 63 9
Men/women (%) 71/29
Body mass index (mean, kg/m2)* 30 6
Risk factors (%)
Diabetes† 49
Hypertension 74
Dyslipidemia 61
Current smoking 14
Past medical history (%)
Coronary heart disease 54
Peripheral arterial disease 18
Stroke or transient ischemic attack 6
No documented vascular disease‡ 39
Concomitant medications (%)
Aspirin 75 mg, clopidogrel or ticlopidine 83
Atorvastatin 100
ACE inhibitor or ARB 68
Beta-blocker 48
Thiazolidinedione 10
Baseline lipid and HbA1c values*
Total cholesterol (mg/dl) 142 28
LDL-C (mg/dl) 67 22
HDL-C (mg/dl) 50 13
Triglycerides (mg/dl) 127 65
HbA1c (%) 6.7 1.04
Baseline biomarker values§
Lp-PLA2 activity (nmol/min/ml) 123 (107, 145)
hs-CRP (mg/l) 1.17 (0.6, 2.5)
IL-6 (ng/l) 2.53 (1.7, 3.5)
MPO (pmol/l) 556 (380, 755)
MMP-9 (g/l) 499 (273, 877)
Presented as arithmetic mean  SD; †denotes diabetes requiring pharmacotherapy; ‡refers to
atients with Framingham Risk Score20%; §presented as geometric mean (interquartile range:
5th, 75th percentile).
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; HbA1c hemoglo-
in subtype A1c; HDL-C high-density lipoprotein cholesterol; hs-CRP high-sensitivity C-reactive
rotein; IL  interleukin; LDL-C  low-density lipoprotein cholesterol; Lp-PLA2  lipoprotein-
ssociated phospholipase A2; MMP-9  matrix metalloproteinase-9; MPO  myeloperoxidase.aseline Lp-PLA2 activity was examined as a continuous aariable, it showed the strongest correlation with baseline
evels of total cholesterol (Pearson r  0.345, p  0.0001),
DL-C (r  0.459, p  0.0001), and inverse correlation
ith HDL-C (r  0.229, p  0.0001). Baseline levels of
p-PLA2 activity and inflammatory biomarkers exhibited
eak and nonsignificant correlations.
ffects of darapladib on Lp-PLA2. As shown in Figure 2,
aseline Lp-PLA2 activity (colorimetric assay) was compa-
able among subjects randomized to placebo or darapladib
0, 80, or 160 mg. In placebo-treated subjects, Lp-PLA2
ctivity remained unchanged over the study duration. In
ontrast, there was a clear dose-dependent reduction of
p-PLA2 activity after 4 weeks of darapladib dosing (first
easurement after randomization), which was also observed
t 12 weeks (p  0.001 for all doses). When compared with
lacebo, the observed inhibition of Lp-PLA2 activity was
ustained at approximately 43%, 55%, and 66% for darap-
adib 40, 80, and 160 mg, respectively. This inhibition
orresponded to achieved levels of Lp-PLA2 activity (nmol/
in/ml) at 12 weeks as follows: placebo: 124 (95% CI 120
o 128), darapladib 40 mg: 68 (95% CI 65 to 71), darapladib
0 mg: 56 (95% CI 53 to 60), and darapladib 160 mg: 43
95% CI 40 to 45). After darapladib discontinuation (15 
days), levels of Lp-PLA2 activity returned toward baseline
lthough they remained lower. In a subset of subjects (n 
23), the enzyme inhibition was confirmed with radiometric
ssay of Lp-PLA2 activity that reproduced the shape of dose
esponse. As shown in Online Figure 1, excellent Pearson
orrelations between the colorimetric and radiometric assays
ere found for the percent inhibition from baseline to week
2 (r  0.97, p  0.0001) and between achieved levels of
p-PLA2 activity at week 12 (r  0.96, p  0.0001).
ipoprotein-associated phospholipase A2 mass was also
easured in a subset of subjects (n  228). Darapladib
educed Lp-PLA2 mass at week 12 compared with placebo
p  0.001 for all doses) but without a dose response (9.6%,
2.9%, and 9.3% reductions by darapladib 40, 80, and 160
g, respectively).
ipid measurements and the effects of darapladib. Treat-
ent with darapladib did not modify total cholesterol,
DL-C, HDL-C, or triglyceride levels at week 4 (not
hown) or at week 12 as compared with placebo (Table 3).
ence, the observed changes in Lp-PLA2 activity levels in
ubjects taking darapladib cannot be attributed to changes in
ipoprotein carriers of this enzyme.
We explored whether atorvastatin dose modified the
ffect of darapladib on change in Lp-PLA2 activity at week
2 and found no significant interaction (p  0.60). We also
xplored whether baseline LDL-C or HDL-C levels influ-
nced inhibition of Lp-PLA2 activity over 12 weeks. There
as no interaction between baseline LDL-C (70 mg/dl
s.70 mg/dl) or HDL-C (40 mg/dl vs.40 mg/dl) and
he change in Lp-PLA2 activity at 12 weeks for all darap-
adib doses (p  0.12 and p  0.13, respectively). Within
he darapladib 160 mg group, achieved levels of Lp-PLA2
ctivity were similar at 12 weeks at different levels of
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Lp-PLA2 and Cardiovascular Biomarkers April 29, 2008:1632–41aseline LDL-C (70 mg/dl [n  94] vs. 70 mg/dl [n 
1]: 42 nmol/min/ml [95% CI 39 to 45 nmol/min/ml] vs.
2 nmol/min/ml [95% CI 38 to 48 nmol/min/ml]; p 
S). Similarly, at different levels of baseline HDL-C, 160
g dose of darapladib produced similar achieved levels of
p-PLA2 activity (40 mg/dl [n  110] vs. 40 mg/dl
n  35]: 40 nmol/min/ml [95% CI 38 to 44 nmol/min/
l] vs. 48 nmol/min/ml [95% CI 41 to 55 nmol/min/ml];
 NS).
ffects of darapladib on biomarkers of CV risk. At
aseline, hs-CRP was low (geometric mean 1.17 mg/l
interquartile range 0.6 to 2.5]), owing to intensive back-
Figure 2 Plasma Lp-PLA2 Activity
The results are presented as geometric means with 95% confidence interval.
All doses of darapladib produced highly significant inhibition of lipoprotein-
associated phospholipase A2 (Lp-PLA2) activity when compared with placebo at
weeks 4 and 12 (p  0.001).
Baseline Lp-PLA2 Activity in Clinical Subgroups
Table 2 Baseline Lp-PLA2 Activity in Clinica
Variable Subgroup n
Age 75 yrs 857
75 yrs 80
Gender Female 268
Male 669
Body mass index 30 kg/m2 528
30 kg/m2 409
Smoking No 806
Current 131
Diabetes No 436
Yes 501
LDL-C 70 mg/dl 537
70 mg/dl 400
HDL-C 40 mg/dl 739
40 mg/dl 198
Atorvastatin 20 mg 462
80 mg 475
Vascular disease No 336
Yes 601
CI  confidence interval; other abbreviations as in Table 1.mround atorvastatin therapy and stable CV status of the
nrolled subject population. Nonetheless, treatment with
arapladib 160 mg (n  161) produced a 20.2% (95% CI
31% to 8%) reduction in hs-CRP at week 12 compared
ith baseline (p  0.003; within group comparison) and a
3.0% (95% CI 18% to 5%) reduction from baseline
ompared with placebo (p  0.15; between groups compar-
son) (Table 4). When response to darapladib was analyzed
ost hoc according to quartiles of baseline Lp-PLA2 activ-
ty, darapladib 160 mg (n  38) significantly reduced
s-CRP in the highest quartile (reduction of 43.2% [95%
I 64% to 11%] relative to placebo [n  43] from 1.17
o 0.79 mg/l in the darapladib 160 mg group vs. 1.26 to 1.45
g/l in the placebo group, p  0.013).
In regard to interleukin-6 (IL-6), the greatest reduc-
ion was again observed with darapladib 160 mg (n 
50) resulting in 21.5% (95% CI 28% to 14%)
eduction from baseline (p  0.001; within group com-
arison) and 12.3% (95% CI 22% to 1%) when
ompared with placebo (p  0.028; between groups
omparison) (Table 4). When response to darapladib was
nalyzed post hoc according to quartiles of baseline
p-PLA2 activity, darapladib 160 mg (n  39) reduced
L-6 in the highest quartile by 20.5% (95% CI 38% to
3%) compared with placebo (n  42) from 2.62 to 2.12
g/l versus 2.56 to 2.62 ng/l (p  0.08). These findings
re not likely attributable to treatment-induced changes
n body weight, because it remained stable over the course
f the study. There were no significant changes in plasma
yeloperoxidase and matrix metalloproteinase-9 in any
reatment groups (Table 4).
Theoretical concern that inhibition of Lp-PLA2 activity
groups
Lp-PLA2 (nmol/min/ml)
p ValueGeometric Mean 95% CI
122 120–124 0.002
133 126–140
113 110–116 0.001
128 125–130
123 121–125 0.18
124 121–126
123 121–125 0.08
127 122–132
129 126–131 0.001
119 116–121
115 113–118 0.001
135 132–138
121 119–123 0.001
134 129–138
130 127–133 0.001
117 114–119
116 113–118 0.001
128 125–130l Subight adversely affect platelet activity prompted us to
e
a
e
b
(
p
s
S
i
s
E
B
W
v astatin
E
B
W
c
1637JACC Vol. 51, No. 17, 2008 Mohler III et al.
April 29, 2008:1632–41 Lp-PLA2 and Cardiovascular Biomarkersxamine the effects of darapladib on several biomarkers
ssociated with enhanced platelet aggregation. There was no
vidence for the increase in any of the measured platelet
iomarkers when analyzed for the changes from baseline
i.e., within group comparison) or in comparison with
ffect of Darapladib on Lipid Parameters
Table 3 Effect of Darapladib on Lipid Parameters
Placebo Dar
Total cholesterol n  184
Baseline 145 28
12 weeks 144 28
Within group comparison 0.7 (3.2 to1.8) 1.9
Between groups comparison N/A 1.6
LDL-C n  181
Baseline 69 23
12 weeks 66 23
Within group comparison 3.2 (5.2 to1.2)* 2.6
Between groups comparison N/A 0.1
HDL-C n  183
Baseline 50 13
12 weeks 50 12
Within group comparison 0.04 (1.0 to1.1) 0.9
Between groups comparison N/A 0.9
Triglycerides n  184
Baseline 127 61
12 weeks 142 65
Within group comparison 14.2 (7.3 to21.2)* 18.8
Between groups comparison N/A 2.0
aseline and week 12 data are presented as means SD (mg/dl). Within group comparisons depic
ithin group comparisons (mg/dl; mean and 95% CI) were analyzed using paired t test. Between
alue, atorvastatin level, and treatment included as covariates. All subjects on concomitant atorv
Abbreviations as in Tables 1 and 2.
ffect of Darapladib on Inflammatory Biomarkers
Table 4 Effect of Darapladib on Inflammatory Biomarkers
Placebo D
hs-CRP (mg/l) n  177
Baseline 1.09
12 weeks 1.06
Within group comparison (%) 3.3 (15 to10) 1
Between groups comparison (%) N/A 
IL-6 (ng/l) n  171
Baseline 2.45
12 weeks 2.28
Within group comparison (%) 6.9 (15 to2) 1
Between groups comparison (%) N/A 
MPO (pmol/l) n  179
Baseline 508
12 weeks 515
Within group comparison (%) 1.4 (6 to10) 
Between groups comparison (%) N/A
MMP-9 (g/l) n  178
Baseline 471
12 weeks 479
Within group comparison (%) 2.0 (9 to13)
Between groups comparison (%) N/A 
aseline and week 12 data are presented as geometric means. Within group comparisons depict c
ithin group comparisons were analyzed using paired t test. Between group comparisons were
ovariates. Values in parenthesis are 95% CI. *p  0.05; †p  0.028.
Abbreviations as in Tables 1 and 2.lacebo (i.e., between groups comparison) at week 4 (not
hown) and week 12 of treatment with darapladib (Table 5).
imilarly, discontinuation of darapladib produced no signif-
cant effect on these measurements at follow-up (not
hown).
b 40 mg Darapladib 80 mg Darapladib 160 mg
67 n  164 n  162
28 143 31 140 27
32 142 31 141 28
to5.9) 1.3 (5.1 to2.6) 1.3 (1.9 to4.5)
to6.1) 0.6 (5.1 to3.9) 0.9 (3.6 to5.3)
66 n  159 n  160
21 68 21 67 21
25 66 23 64 22
to0.7) 2.6 (5.4 to0.2) 2.4 (5.1 to0.3)
to3.6) 0.6 (3.0 to4.1) 0.2 (3.3 to3.8)
67 n  164 n  162
13 49 13 49 13
12 48 12 50 11
to1.9) 0.2 (1.3 to1.0) 1.4 (0.3 to2.5)*
to2.2) 0.6 (2.0 to0.7) 1.0 (0.3 to2.4)
67 n  164 n  162
48 135 80 126 70
67 145 98 137 73
to26.3)* 10.5 (3.2 to24.2) 10.9 (2.0 to19.8)*
to14.5) 1.6 (14.2 to11.0) 3.7 (16.4 to8.8)
es from baseline. Between group comparisons indicate changes from baseline relative to placebo.
comparisons (mg/dl; mean and 95% CI) were analyzed with analysis of covariance with baseline
20 or 80 mg. Similar results were obtained comparing week 4 of treatment. *p  0.05.
dib 40 mg Darapladib 80 mg Darapladib 160 mg
166 n  161 n  161
1.14 1.03 1.28
1.02 1.02 1.02
22 to3) 1.5 (17 to17) 20.2 (31 to8)*
22 to13) 0.3 (18 to20) 13.0 (18 to5)
149 n  146 n  150
2.57 2.35 2.73
2.17 2.17 2.14
23 to7)* 7.3 (16 to2) 21.5 (28 to14)*
18 to4) 2.3 (12 to10) 12.3 (22 to1)†
165 n  162 n  163
8 524 588
2 530 586
9 to8) 1.1 (8 to11) 0.3 (10 to10)
9 to14) 0.9 (10 to13) 4.7 (6 to17)
165 n  161 n  163
5 448 475
5 421 505
13 to11) 6 (17 to5) 6.0 (6 to20)
14 to15) 9.8 (22 to4) 4.8 (9 to21)
from baseline. Between groups comparisons indicate changes from baseline relative to placebo.
d with analysis of covariance with baseline value, atorvastatin level, and treatment included asapladi
n  1
141
143
(2.2
(2.8
n  1
67
65
(5.8
(3.4
n  1
50
51
(0.2
(0.5
n  1
118
137
(11.4
(10.5
t chang
grouparapla
n 
0.5 (
6.0 (
n 
5.5 (
7.8 (
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55
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1.1 (
1.6 (
n 
50
49
2 (
0.8 (
hanges
analyze
A
o
d
e
d
(
n
d
r
w
i
g
T
a
(
1
f
p
3
i
c
w
e
d
f
h
r
g
n
o
t

a
i
4
m
D
K
t
C
s
s
T
l
r
h
p
t
p
t
R
m
t
c
a
(
w
a
f
n
L
C
s
L
o
E
B
W
c
2.
1638 Mohler III et al. JACC Vol. 51, No. 17, 2008
Lp-PLA2 and Cardiovascular Biomarkers April 29, 2008:1632–41dverse events. There were no clinically important effects
n vital signs, electrocardiograms, or laboratory data in the
arapladib groups compared with placebo. Serious adverse
vents were reported in 3% in the placebo (n  7) and
arapladib 40 mg (n 6) and 80 mg (n 7) groups and 2%
n  5) in the darapladib 160 mg group. These events were
ot concentrated in any particular organ system class and
isplayed no dose-related pattern. No deaths occurred after
andomization to darapladib or placebo. The CV events
ere infrequent at 2% in the placebo group (n  4), 1%
n the darapladib 40 and 80 mg groups (n  2 in both
roups), and 1% in the darapladib 160 mg group (n  3).
he most commonly reported serious adverse event was
ngina at1% in the placebo (n 2) and darapladib 40 mg
n  1) groups, none in the darapladib 80 mg group, and
% (n  3) in the darapladib 160 mg group.
A total of 3% (n  33) of subjects prematurely withdrew
rom study drug due to an adverse event; 2% (n  4) in the
lacebo group, 4% (n  10) in the darapladib 40 mg group,
% (n 8) in the darapladib 80 mg group, and 5% (n 11)
n the darapladib 160 mg group. Within each organ system
lass, the incidence of adverse events leading to premature
ithdrawal was 1% across all treatment groups with the
xception of a 3% (n  6) incidence of premature with-
rawals due to gastrointestinal events (mostly change in
eces odor or diarrhea) in the darapladib 160 mg group. A
igher incidence of odor- (mainly feces or urine) or taste-
elated events was reported in all darapladib treatment
roups (33% to 36%) compared with placebo (21%) that did
ot lead to frequent premature withdrawals (1% incidence
f withdrawals due to odor- or taste-related events across all
reatment groups).
No cases of rhabdomyolysis or creatine kinase elevation
10  upper normal limit were reported. Elevation of
ffect of Darapladib on Platelet-Related Biomarkers
Table 5 Effect of Darapladib on Platelet-Related Biomarkers
Placebo
P-selectin (g/l) n  177
Baseline 49.21
12 weeks 47.10
Within group comparison (%) 4.3 (9 to1)
Between groups comparison (%) N/A
CD40L (pg/ml) n  174
Baseline 354.96
12 weeks 355.15
Within group comparison (%) 0 (12 to14)
Between groups comparison (%) N/A
U-11-dehydro-TxB2 (ng/mmol Cr) n  168
Baseline 56.58
12 weeks 50.73
Within group comparison (%) 10.0 (17 to3)*
Between groups comparison (%) N/A
aseline and 12 week data are presented as geometric means. Within group comparisons depict c
ithin group comparisons were analyzed using paired t test. Between group comparisons were
ovariates. Values in parentheses are 95% confidence interval. *p  0.05.
CD40L  CD40 ligand; Cr  creatinine; U-11-dehydro-TxB2  urinary 11-dehydrothromboxane Blanine transaminase3 upper limit of normal was noted sn 1% (n  1) in placebo, 1% (n  2) in the darapladib
0 and 80 mg groups, and 1% (n 3) in the darapladib 160
g group.
iscussion
ey findings. This is the first report of chronic adminis-
ration of an Lp-PLA2 inhibitor, darapladib, in CHD or
HD-risk equivalent patients in the setting of intensive
tatin therapy. There was a significant dose-dependent and
ustained reduction of Lp-PLA2 activity with darapladib.
he effect was independent of baseline LDL-C or HDL-C
evels and background atorvastatin regimen. In addition, the
esults suggested a possible anti-inflammatory effect of the
ighest dose of darapladib treatment when applied to
atients receiving atorvastatin therapy. In regards to safety,
here were no adverse effects of darapladib on biomarkers of
latelet activity and no major safety concerns emerged from
his study.
elationship between Lp-PLA2, lipoproteins, and treat-
ent of dyslipidemia. Owing to its binding to carboxyl-
erminus of human apolipoprotein B, approximately 80% of
irculating Lp-PLA2, measured as mass or activity, is
ssociated with apolipoprotein B–containing lipoproteins
22,23). The remaining Lp-PLA2 is less firmly associated
ith phospholipid moiety of HDL-C and does not bind to
polipoprotein A-I. Higher Lp-PLA2 mass or activity are
ound in pro-atherogenic small dense LDL-C and electro-
egative LDL-C particles, as opposed to large buoyant
DL-C and electropositive subfractions, respectively (24–26).
onsistent with this distribution of Lp-PLA2, our findings
how strong correlations between Lp-PLA2 activity and
DL-C and inverse relationship with HDL-C in patients
n intensive atorvastatin treatment. Prior studies have also
pladib 40 mg Darapladib 80 mg Darapladib 160 mg
n  162 n  158 n  151
49.11 46.80 48.54
47.37 44.33 46.47
(9 to1) 5.0 (11 to2) 4.3 (9 to1)
(6 to8) 3 (10 to4) 0 (7 to7)
n  162 n  158 n  159
392.06 338.93 335.37
359.67 333.15 356.26
(19 to3) 2.0 (17 to17) 6.0 (7 to21)
(11 to14) 3.9 (11 to14) 3.4 (13 to22)
n  158 n  158 n  154
55.53 52.73 54.74
47.92 48.20 49.75
(23 to4)* 9.0 (17 to0.4) 9.0 (19 to1)
(16 to8) 0.6 (12 to13) 0.2 (12 to13)
from baseline. Between groups comparisons indicate changes from baseline relative to placebo.
d with analysis of covariance with baseline value, atorvastatin level, and treatment included asDara
3.9
1
8.0
3.9
14.0
4.5
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April 29, 2008:1632–41 Lp-PLA2 and Cardiovascular Biomarkersbrate, ezetimibe) decrease plasma Lp-PLA2 mass or activ-
ty due to LDL-C lowering, without a direct effect on
acrophage expression of the enzyme (27,28). Comparisons
cross studies are difficult, because of the use of several
ethods to measure Lp-PLA2 mass or activity. In general,
owever, statin treatment alone (e.g., pravastatin, fluva-
tatin, simvastatin, atorvastatin) has been associated with
pproximately 20% to 30% reduction in the measurements of
p-PLA2 (mass or activity) in stable CV patients (29–31).
imilarly, other lipid modifying drugs, such as ezetimibe and
enofibrate, modestly lower Lp-PLA2 (mass or activity) (32).
his study shows that a specific Lp-PLA2 inhibitor, darap-
adib, produces substantial additional reductions in Lp-
LA2 activity when added to intensive atorvastatin therapy
up to 66%). This effect was largely independent of atorva-
tatin dose and preserved in clinically relevant strata of
DL-C and HDL-C values.
elationship between Lp-PLA2 and inflammatory bio-
arkers. Oxidatively truncated phospholipids are sub-
trates for Lp-PLA2 that promote formation of putative
ro-inflammatory and pro-apoptotic products (9). The
oncentration of oxidized LDL-C within human atheroma
s approximately 70-fold higher than in circulation; thus, the
omparisons between Lp-PLA2 and other inflammatory
arkers in plasma might not accurately reflect intralesional
nter-dependency (33). In this context, it is not surprising
hat circulating Lp-PLA2 shows weak correlations with
ther inflammatory biomarkers, as shown in this and
revious studies (34,35). Nonetheless, increasing levels of
p-PLA2 have been reported to have additive effects with
s-CRP or oxidized phospholipid/apolipoprotein B ratio in
redicting the risk of CV events (14,16,36). When assessing
he effects of Lp-PLA2 inhibition on soluble inflammatory
iomarkers, it is important to underscore that baseline
s-CRP levels were lower in this study compared with other
nvestigations using intensive atorvastatin treatment and there-
ore might have minimized the opportunity to observe addi-
ional effects on this biomarker (5,6,37,38). Despite these
aveats, a significant reduction in hs-CRP was noted in the
ighest darapladib group (160 mg) after 12 weeks of treatment
within group comparison). Interestingly, the darapladib 160
g group also exhibited a significant reduction in IL-6 (within
roup and between groups comparisons). This finding is
oteworthy, because IL-6 is a trigger for hepatic production of
s-CRP and it is less affected by background atorvastatin
reatment (37,39).
elationship between Lp-PLA2 and PAF. Initial de-
criptions of Lp-PLA2 focused on the ability of this enzyme
o degrade PAF, a potent pro-inflammatory lipid mediator
hat is also implicated in platelet aggregation (10). However,
esponsiveness to PAF is not altered in Japanese subjects
ith a genetic variant in Lp-PLA2 (Val276Phe) that results
n the absence of circulating enzyme (40). In addition, other
linical trials failed to show measurable benefit of recombi-
ant human Lp-PLA2 in conditions suspected to be PAF-
ediated (e.g., severe sepsis, asthma) (41,42). These obser- pations together suggested that other extra- and intracellular
nzymatic pathways are involved in hydrolysis of PAF,
ndependent of Lp-PLA2 activity. To this end, studies
dentified several PAF inactivating enzymes, including
ecithin-cholesterol acetyl transferase and unrelated phos-
holipases (e.g., group X secretory PLA2 and intracellular
AF-AH [II]) (43,44). These findings provide mechanistic
xplanation for the lack of detrimental effect of darapladib
n platelet biomarkers despite high levels of Lp-PLA2
nhibition. The importance of our findings is also under-
cored by the fact that several biomarkers were studied,
ncluding urinary 11-dehydrothromboxane B2, which is less
ffected by pre-analytical artifacts associated with the measure-
ents of circulating markers (45).
tudy limitations. There are several limitations of this
tudy to be emphasized. First, the clinical relevance of the
bserved Lp-PLA2 inhibition with darapladib must await
vidence linking Lp-PLA2 inhibition to a beneficial effect
n clinical events. Nonetheless, marked inhibition of the
nzyme activity in the presence of intensive background
tatin therapy is an important pre-requisite for testing this
oncept in high-risk CV patients. Second, our study cannot
ddress the effects of Lp-PLA2 inhibition within atheroma
hat is postulated to be ultimately responsible for clinical
enefits. It is important to underscore, however, that com-
arable exposures of darapladib inhibit intralesional Lp-
LA2 activity in the clinical setting (46). Third, the effects
n IL-6 and hs-CRP were modest and limited to the
ighest dose of darapladib. These results might be viewed as
ypothesis-generating and will require replication in other
tudies.
onclusions
lthough treatment with statins has resulted in improved
rognosis in primary and secondary prevention populations,
igh-risk individuals continue to experience recurrent CV
vents despite adequate treatment. It is postulated that
nflammatory mediators not addressed by LDL-C lowering
ontribute to plaque instability and thrombotic events. The
esults of this study indicate that darapladib produces
ubstantial inhibition of Lp-PLA2 activity in the presence of
ntensive statin therapy and suggest that such intervention
ight result in additional systemic anti-inflammatory ef-
ects. Future studies are required to determine whether
hronic Lp-PLA2 inhibition will stabilize high-risk lesions
nd potentially reduce CV events.
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